Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

NCT01281592 is registered in ClinicalTrials.gov with Aptose Biosciences Inc. as lead sponsor.

NCT NCT01281592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01281592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
Lead sponsor
Aptose Biosciences Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
January 31, 2014
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumours